Exploring the Booming Pharmaceutical Contract Development Market by 2026
In 2021, Lonza Group (Switzerland) entered into an agreement with Aruvant Science (US) to carry out process development (one-time investigational gene therapy-ARU-1801) for sickle-cell treatment in the US
View full press release